{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T03:22:21Z","timestamp":1790565741570,"version":"4.1.0"},"reference-count":63,"publisher":"American Society for Microbiology","issue":"5","license":[{"start":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T00:00:00Z","timestamp":1714608000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T00:00:00Z","timestamp":1714608000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["23fk0108604"],"award-info":[{"award-number":["23fk0108604"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2024,5,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      Japan is a country with an approximate 10% prevalence rate of carbapenem-resistant\n                      <jats:italic>Pseudomonas aeruginosa<\/jats:italic>\n                      (CRPA). Currently, a comprehensive overview of the genotype and phenotype patterns of CRPA in Japan is lacking. Herein, we conducted genome sequencing and quantitative antimicrobial susceptibility testing for 382 meropenem-resistant CRPA isolates that were collected from 78 hospitals across Japan from 2019 to 2020. CRPA exhibited susceptibility rates of 52.9%, 26.4%, and 88.0% against piperacillin\u2013tazobactam, ciprofloxacin, and amikacin, respectively, whereas 27.7% of CRPA isolates was classified as difficult-to-treat resistance\n                      <jats:italic>P. aeruginosa<\/jats:italic>\n                      . Of the 148 sequence types detected, ST274 (9.7%) was predominant, followed by ST235 (7.6%). The proportion of urine isolates in ST235 was higher than that in other STs (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.0056, \u03c7\n                      <jats:sup>2<\/jats:sup>\n                      test). Only 4.1% of CRPA isolates carried the carbapenemase genes:\n                      <jats:italic>bla<\/jats:italic>\n                      <jats:sub>GES<\/jats:sub>\n                      (2) and\n                      <jats:italic>bla<\/jats:italic>\n                      <jats:sub>IMP<\/jats:sub>\n                      (13). One ST235 isolate carried the novel\n                      <jats:italic>bla<\/jats:italic>\n                      <jats:sub>IMP<\/jats:sub>\n                      variant\n                      <jats:italic>bla<\/jats:italic>\n                      <jats:sub>IMP-98<\/jats:sub>\n                      in the chromosome. Regarding chromosomal mutations, 87.1% of CRPA isolates possessed inactivating or other resistance mutations in\n                      <jats:italic>oprD<\/jats:italic>\n                      , and 28.8% showed mutations in the regulatory genes (\n                      <jats:italic>mexR<\/jats:italic>\n                      ,\n                      <jats:italic>nalC<\/jats:italic>\n                      , and\n                      <jats:italic>nalD<\/jats:italic>\n                      ) for the MexAB-OprM efflux pump. Additionally, 4.7% of CRPA isolates carried a resistance mutation in the PBP3-encoding gene\n                      <jats:italic>ftsI<\/jats:italic>\n                      . The findings from this study and other surveillance studies collectively demonstrate that CRPA exhibits marked genetic diversity and that its multidrug resistance in Japan is less prevailed than in other regions. This study contributes a valuable data set that addresses a gap in genotype\/phenotype information regarding CRPA in the Asia\u2013Pacific region, where the epidemiological background markedly differs between regions.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1128\/aac.01669-23","type":"journal-article","created":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T15:22:17Z","timestamp":1712071337000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":37,"title":["Nationwide genome surveillance of carbapenem-resistant\n                    <i>Pseudomonas aeruginosa<\/i>\n                    in Japan"],"prefix":"10.1128","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5144-3459","authenticated-orcid":true,"given":"Hirokazu","family":"Yano","sequence":"first","affiliation":[{"name":"Antimicrobial Resistance Research Center, National Institute of Infectious Diseases, Higashimurayama, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3430-8524","authenticated-orcid":true,"given":"Wataru","family":"Hayashi","sequence":"additional","affiliation":[{"name":"Antimicrobial Resistance Research Center, National Institute of Infectious Diseases, Higashimurayama, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayoko","family":"Kawakami","sequence":"additional","affiliation":[{"name":"Antimicrobial Resistance Research Center, National Institute of Infectious Diseases, Higashimurayama, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadao","family":"Aoki","sequence":"additional","affiliation":[{"name":"Antimicrobial Resistance Research Center, National Institute of Infectious Diseases, Higashimurayama, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiko","family":"Anzai","sequence":"additional","affiliation":[{"name":"Antimicrobial Resistance Research Center, National Institute of Infectious Diseases, Higashimurayama, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zuo","sequence":"additional","affiliation":[{"name":"Antimicrobial Resistance Research Center, National Institute of Infectious Diseases, Higashimurayama, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3738-3545","authenticated-orcid":false,"given":"Norikazu","family":"Kitamura","sequence":"additional","affiliation":[{"name":"Antimicrobial Resistance Research Center, National Institute of Infectious Diseases, Higashimurayama, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3115-0645","authenticated-orcid":false,"given":"Aki","family":"Hirabayashi","sequence":"additional","affiliation":[{"name":"Antimicrobial Resistance Research Center, National Institute of Infectious Diseases, Higashimurayama, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7576-2654","authenticated-orcid":false,"given":"Toshiki","family":"Kajihara","sequence":"additional","affiliation":[{"name":"Antimicrobial Resistance Research Center, National Institute of Infectious Diseases, Higashimurayama, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2420-3542","authenticated-orcid":false,"given":"Shizuo","family":"Kayama","sequence":"additional","affiliation":[{"name":"Antimicrobial Resistance Research Center, National Institute of Infectious Diseases, Higashimurayama, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9897-3905","authenticated-orcid":true,"given":"Yo","family":"Sugawara","sequence":"additional","affiliation":[{"name":"Antimicrobial Resistance Research Center, National Institute of Infectious Diseases, Higashimurayama, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4289-1115","authenticated-orcid":false,"given":"Koji","family":"Yahara","sequence":"additional","affiliation":[{"name":"Antimicrobial Resistance Research Center, National Institute of Infectious Diseases, Higashimurayama, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9252-7739","authenticated-orcid":true,"given":"Motoyuki","family":"Sugai","sequence":"additional","affiliation":[{"name":"Antimicrobial Resistance Research Center, National Institute of Infectious Diseases, Higashimurayama, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02185-7"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2011.00065"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00031-19"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.2.349"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13100-018-0141-4"},{"key":"e_1_3_5_7_2","unstructured":"World Health Organization. 2017. WHO priority pathogens list for R&D of new antibiotics. Available from: https:\/\/www.who.int\/news\/item\/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed. Retrieved 8 Nov 2023."},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00001-07"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-5247(22)00329-9"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-021-04308-0"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1348-0421.2009.00137.x"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/JB.182.5.1410-1414.2000"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2958.2004.04210.x"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/JB.01342-06"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky364"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlac060"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02000-21"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkad127"},{"key":"e_1_3_5_19_2","unstructured":"World Health Organization. 2022. Global antimicrobial resistance and use surveillance system (GLASS) report: 2021 report electronic supplementary material. Available from: https:\/\/www.who.int\/publications\/i\/item\/9789240027336. Retrieved 8 Nov 2023."},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.7883\/yoken.JJID.2020.499"},{"key":"e_1_3_5_21_2","unstructured":"Ministry of Health Labour and Welfare of Japan. 2021. JANIS open report clinical laboratory-division. Available from: https:\/\/janis.mhlw.go.jp\/english\/report\/index.html. Retrieved 8 Nov 2023."},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.1186\/s44280-023-00009-9"},{"key":"e_1_3_5_23_2","unstructured":"European Centre for Disease Prevention and Control. 2022. Antimicrobial resistance in the EU\/EEA (EARS-Net) - annual epidemiological report for 2020. Available from: https:\/\/www.ecdc.europa.eu\/sites\/default\/files\/documents\/EUEEA_trend_tables_for_individual_isolates_2020.pdf. Retrieved 8 Nov 2023."},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-43516-4"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1478"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2011.03570.x"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.12688\/wellcomeopenres.14826.1"},{"key":"e_1_3_5_28_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-016-0997-x"},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.106196"},{"key":"e_1_3_5_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkj014"},{"key":"e_1_3_5_31_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-91456-0"},{"key":"e_1_3_5_32_2","doi-asserted-by":"publisher","DOI":"10.1099\/00221287-146-11-2855"},{"key":"e_1_3_5_33_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13100-023-00295-5"},{"key":"e_1_3_5_34_2","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms10040700"},{"key":"e_1_3_5_35_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0271627"},{"key":"e_1_3_5_36_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2958.1999.01548.x"},{"key":"e_1_3_5_37_2","unstructured":"Pfeiffer F. 2015. TnAs3. Available from: https:\/\/isfinder.biotoul.fr\/scripts\/ficheIS.php?name=TnAs3. Retrieved 1 Feb 2024."},{"key":"e_1_3_5_38_2","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.02589-23"},{"key":"e_1_3_5_39_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/26.2.391"},{"key":"e_1_3_5_40_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00170-13"},{"key":"e_1_3_5_41_2","doi-asserted-by":"publisher","DOI":"10.1099\/mic.0.054320-0"},{"key":"e_1_3_5_42_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02629-17"},{"key":"e_1_3_5_43_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp142"},{"key":"e_1_3_5_44_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04207-14"},{"key":"e_1_3_5_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2020.09.010"},{"key":"e_1_3_5_46_2","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics10101189"},{"key":"e_1_3_5_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2015.08.002"},{"key":"e_1_3_5_48_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00802-13"},{"key":"e_1_3_5_49_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-05621-5"},{"key":"e_1_3_5_50_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku267"},{"key":"e_1_3_5_51_2","unstructured":"Food and Drug Administration. 2017. 510(k) substantial equivalence determination decision summary: K162740. Available from: https:\/\/www.accessdata.fda.gov\/cdrh_docs\/reviews\/K162740.pdf. Retrieved 1 Feb 2024."},{"key":"e_1_3_5_52_2","unstructured":"Food and Drug Administration. 2019. 510(k) substantial equivalence determinatinon decision summary: K192355. Available from: https:\/\/www.accessdata.fda.gov\/cdrh_docs\/reviews\/K192355.pdf. Retrieved 1 Feb 2024."},{"key":"e_1_3_5_53_2","unstructured":"Food and Drug Administration. 2020. 510(K) substantial equivalence determination decision summary: K202343. Available from: https:\/\/www.accessdata.fda.gov\/cdrh_docs\/reviews\/K202343.pdf. Retrieved 1 Feb 2024."},{"key":"e_1_3_5_54_2","unstructured":"Food and Drug Administration. 2020. 510(k) substantial equivalence determination decision summary: K193536. Available from: https:\/\/www.accessdata.fda.gov\/cdrh_docs\/reviews\/K193536.pdf. Retrieved 1 Feb 2024."},{"key":"e_1_3_5_55_2","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/bty560"},{"key":"e_1_3_5_56_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-019-0072-8"},{"key":"e_1_3_5_57_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0112963"},{"key":"e_1_3_5_58_2","doi-asserted-by":"publisher","DOI":"10.1101\/gr.232397.117"},{"key":"e_1_3_5_59_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-2836(05)80360-2"},{"key":"e_1_3_5_60_2","doi-asserted-by":"publisher","DOI":"10.1093\/molbev\/mst010"},{"key":"e_1_3_5_61_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkn072"},{"key":"e_1_3_5_62_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-9-376"},{"key":"e_1_3_5_63_2","unstructured":"Antimicrobial Resistance Research Center National Institute of Infectious Diseases. 2024. Genome assemblies of 382 carbapenem-resistant Pseudomonas aeruginosa isolates collected from Japanese hospitals in 2019\u20132020. Zenodo. Available from: https:\/\/doi.org\/10.5281\/zenodo.10693593. Retrieved 22 Feb 2024."},{"key":"e_1_3_5_64_2","unstructured":"Yano H. 2024. PubMLST allele profiles and sequence alignments of 382 carbapenem-resistant Pseudomonas aeruginosa isolates collected from Japanese hospitals in 2019\u20132020. Zenodo. Available from: https:\/\/doi.org\/10.5281\/zenodo.10693794. Retrieved 22 Feb 2024."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.01669-23","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.01669-23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T09:03:53Z","timestamp":1714640633000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/aac.01669-23"}},"subtitle":[],"editor":[{"given":"Pranita D.","family":"Tamma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,5,2]]},"references-count":63,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5,2]]}},"alternative-id":["10.1128\/aac.01669-23"],"URL":"https:\/\/doi.org\/10.1128\/aac.01669-23","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,2]]},"assertion":[{"value":"2023-12-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-11","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-02","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01669-23"}}